Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06937086 · ClinicalTrials.gov registry record · Phase 3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
A Phase 3 study of Ulcerative Colitis and Obesity or Overweight, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 350
- Enrollment target
- 20
- Study locations
NCT06937086: Recruiting Phase 3 study of Ulcerative Colitis and Obesity or Overweight, sponsored by Eli Lilly and Company.
NCT06937086 is a Phase 3 study of Ulcerative Colitis and Obesity or Overweight that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 350 participants, below the 2,055-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06937086, a Phase 3 study of Ulcerative Colitis and Obesity or Overweight, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 350 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight. Participation in this study will last up to 61 weeks, including 52 weeks of treatment.
Primary Outcome
Percentage of participants who simultaneously achieve clinical remission and at least 10% weight reduction.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tirzepatide
- DRUG Mirikizumab
Study Locations (20)
Florida
- Research Associates of South Florida - Miami - Southwest 8th Street - Miami
- Gastro Health Research - Miami - Miami
- Orlando Health - Orlando
- Digestive and Liver Center of Florida - Orlando
- Gastro Health Research - Pensacola - Pensacola
- Precision Clinical Research - Sunrise
California
- Smart Cures Clinical Research - Anaheim
- Cedars-Sinai Medical Center - Beverly Hills
- United Medical Doctors - Los Alamitos - Los Alamitos
- California Medical Research Associates - Northridge
Indiana
- Indiana University Health University Hospital - Indianapolis
- Gastroenterology Health Partners - New Albany
Louisiana
- Care Access - New Iberia - New Iberia
- Louisiana Research Center - Shreveport
Alabama
- Digestive Health Specialists - Dothan
Idaho
- Grand Teton Research Group - Idaho Falls
Illinois
- Rush University Medical Center - Chicago
Kentucky
- Gastroenterology Health Partners - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2025-06-26 |
| Est. Completion | 2028-04 |
| Phase | Phase 3 |
What NCT06937086 shows while recruiting
NCT06937086 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, below the 2,055-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (83% lower).
The record links to 2 conditions, with Ulcerative Colitis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06937086 names 20 study sites across 10 states, led by Florida, California, Indiana.
Frequently Asked Questions
What is clinical trial NCT06937086 about?
NCT06937086 is a clinical study titled "Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study". The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight. Participation ...
What is the current status of trial NCT06937086?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 350 participants. The study started on 2025-06-26. Estimated completion is 2028-04.
What conditions does trial NCT06937086 study?
This clinical trial studies the following conditions: Ulcerative Colitis, Obesity or Overweight.
What interventions are being tested in trial NCT06937086?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG), Mirikizumab (DRUG).
Who is sponsoring clinical trial NCT06937086?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06937086 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06937086's enrollment target sits among peer trials
350 29th of 122 higher than 94 of 122 other Ulcerative Colitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ulcerative Colitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 3
-
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
RECRUITING · Phase 3
-
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 3
-
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
RECRUITING · Phase 3
-
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
RECRUITING · Phase 3
-
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI